Neurocrine Biosciences (NBIX) Long-Term Debt Repayments (2020 - 2022)

Neurocrine Biosciences' Long-Term Debt Repayments history runs 3 years deep, the most recent figure standing at $279.0 million for Q2 2022.

• Quarterly Long-Term Debt Repayments changed N/A year-over-year to $279.0 million in Q2 2022, while the trailing twelve-month figure through Sep 2023 was $279.0 million (changed 0.0% YoY) and the FY2024 annual result came in at $308.8 million, changed N/A from the prior year.
• Long-Term Debt Repayments was $279.0 million for Q2 2022 at Neurocrine Biosciences, up from $100000.0 in the prior quarter.
• Across five years, Long-Term Debt Repayments topped out at $279.0 million in Q2 2022 and bottomed at $100000.0 in Q1 2021.
• A 3-year average of $155.3 million and a median of $186.9 million in 2020 frame the typical range for Long-Term Debt Repayments.